Gelesis Holdings Long Term Debt 2021-2022 | GLS
Gelesis Holdings long term debt from 2021 to 2022. Long term debt can be defined as the sum of all long term debt fields.
| Gelesis Holdings Annual Long Term Debt (Millions of US $) |
|
|---|---|
| 2021 | $ |
| 2020 | $ |
| 2019 | $ |
| Gelesis Holdings Quarterly Long Term Debt (Millions of US $) |
|
|---|---|
| 2022-03-31 | $34 |
| 2021-12-31 | $35 |
| 2021-09-30 | |
| 2021-06-30 | |
| 2021-03-31 | |
| 2020-12-31 | |
| 2020-09-30 | |
| 2020-06-30 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Biomedical and Genetics | $0.104B | $0.011B |
| Gelesis is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Gelesis, formerly known as Capstar Special Purpose Acquisition Corp., is based in BOSTON. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bristol Myers Squibb (BMY) | United States | $160.059B | 9.71 |
| GSK (GSK) | United Kingdom | $81.408B | 9.78 |
| Bio-Rad Laboratories (BIO.B) | United States | $15.412B | 34.05 |
| QIAGEN (QGEN) | Netherlands | $11.018B | 18.45 |
| Biohaven Pharmaceutical Holding (BHVN) | United States | $10.535B | 0.00 |
| Ginkgo Bioworks Holdings (DNA) | United States | $5.561B | 0.00 |
| Arcus Biosciences (RCUS) | United States | $1.821B | 35.53 |
| Myovant Sciences (MYOV) | United Kingdom | $1.600B | 0.00 |
| Emergent Biosolutions (EBS) | United States | $1.482B | 8.59 |
| Zymeworks (ZYME) | Canada | $0.390B | 0.00 |
| Enzo Biochem (ENZ) | United States | $0.120B | 0.00 |
| SQZ Biotechnologies (SQZ) | United States | $0.097B | 0.00 |
| Ambrx Biopharma (AMAM) | United States | $0.089B | 0.00 |
| ADC Therapeutics SA (ADCT) | Switzerland | $0.000B | 0.00 |
